CURIUM

📅 Upcoming

🕒 Recent(90d)

News

• FDA clears first generic radioligand drug; Sionna turns to layoffs
  A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.
  biopharma_dive · 2d ago
• FDA approves first radioligand generic, setting up rivalry with Novartis
  For the first time, Novartis’ leadership in the radioligand field will be tested by a generic rival. Curium announced on Monday that the FDA has approved its “radioligand equivalent” to Novartis’ L…
  endpoints · 2d ago
• Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency
  While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate believing a competing product can make the supply chain more resilient.
  biospace · 23d ago
• FDA clears Lantheus’ Alzheimer’s PET imaging agent Tauklarify
  Lantheus, which recently agreed to an $8 billion takeover by fellow radiopharma Curium, garnered FDA clearance for its Alzheimer’s PET imaging agent Tauklarify.
  fiercebiotech · 1mo ago
• Curium buys radiopharma rival Lantheus for $8B; Sandoz settles price-fixing case
  ☢️ Curium spends $8B for Lantheus: Curium is buying fellow radiopharma company Lantheus for $102.5 per share. Lantheus shareholders may receive $12 more per share if certain targets are achieved ...
  endpoints · 1mo ago
• Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
  Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”
  biospace · 1mo ago
• Curium strikes up to $8B deal for radiopharma rival Lantheus
  Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a deal worth up to $8 billion.
  fiercebiotech · 1mo ago
• Hikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drug
  Plus, news about West Pharmaceutical, Stallergenes Greer and Curium: 🏭 Hikma’s US expansion: The generic drugmaker is investing $267 million in Ohio. Its existing factory in Columbus will get $216…
  endpoints · 3mo ago